In addition to the association between inherited ovarian cancer and RAD51, BRIP, and PALB2 pathogenic variants, MUTHY pathogenic variants confer an increased risk of ovarian cancer and may demonstrate resistance to platinum-based agents, much like tumours with mismatch repair deficiency [39]. This evidence concerns the gene RAD51 and neoplasm.